A planned health plan deal will extend oncology services across states covering about 1 million people

Evolent Health announced new and renewed contracts, including an expansion of oncology services covering about 1 million people. The company reported Q3 2026 revenue of $725.4M, a net loss of $23.6M, and adjusted EBITDA of $34.3M. CEO Seth Blackley highlighted growth from existing clients and strong performance in oncology launches, expecting AI and oncology solutions to drive future growth.

Original reporting
Published Nov 5, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$EVH
Bullish
high confidence
Mentioned
$EVH
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$EVHBullishHigh
01

Why it matters

The earnings beat and contract wins suggest a turnaround in profitability, but margin pressures remain.

02

Market read

Evolent's results could influence peer health‑tech stocks and sector sentiment.

03

What to watch

Potential margin pressure from higher medical expense ratios could offset revenue growth.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Evolent Health is a provider of AI‑driven specialty care solutions to health plans.

Company-level read

Ticker impact

$EVHBullishHigh confidence
Context

Evolent Health reported Q3 2026 results with revenue of $725.4M and a narrowed net loss, plus new oncology service agreements covering ~1M lives.

Expected impact

likely upside as the market prices in improved earnings and growth from new contracts

Evidence & confidence

Revenue beat and loss narrowing are fresh data; the oncology expansion adds growth visibility, prompting buying pressure.

Market effects

Strengthens outlook for health‑tech and specialty care providers.

Positive for U.S. healthcare services sector.

Limited to U.S. health‑tech investors.

Counterpoint

If the oncology expansion faces implementation delays, the earnings beat may be short‑lived.

Key entities

  • Seth Blackley

    Co‑Founder and CEO of Evolent Health, quoted on growth outlook.

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.